

# Lysis of Tumor Cells by Natural Killer Cells in Mice Is Impeded by Platelets<sup>1</sup>

Bernhard Nieswandt, Michael Hafner, Bernd Echtenacher, and Daniela N. Männel<sup>2</sup>

Department of Pathology, Tumor Immunology, University of Regensburg, 93042 Regensburg, Germany

## ABSTRACT

Natural killer (NK) cells provide effective antitumoral activity in the blood stream of mice, leading to reduced metastasis. There are, however, tumor cells that metastasize despite the presence of an intact NK system. The capability of tumor cells to induce platelet aggregation, on the other hand, correlates with their enhanced metastatic potential. A counteractive role of platelets for the NK function in metastasis has never been conceived. Here we demonstrate for the first time that platelets directly protect tumor cells from NK lysis *in vitro* as well as *in vivo*. Using three different tumor cell lines in a mouse model of experimental metastasis, tumor seeding in the target organs was reduced when the host was platelet depleted, but only if the tumor cells were NK sensitive. Aggregation of platelets around tumor cells also inhibited *in vitro* NK tumorlytic activity. This protection of tumor cells by platelets was mouse strain independent and was equally observed with platelets from  $\beta_2$ -microglobulin-deficient mice, excluding a NK inhibitory function of MHC class I on platelets. Thus, even if tumor cells are NK susceptible and cytotoxic NK cells threaten their survival in the blood, platelets are capable of protecting them from cytolysis, thereby promoting metastasis. Surface shielding by platelet aggregates seems to be the main mechanism of this protection.

## INTRODUCTION

Metastasis is a complex phenomenon and involves a series of cellular interactions in which tumor cells disconnect from the primary tumor tissue, intravasate, attach to the vessel wall, and perform diapedesis to push through the endothelial layer and basement membrane. Metastasis can be regarded as a series of events in which at each step certain tumor cells with specific properties are selected (1). During the hematogenous phase of metastasis when the tumor cells are in the blood, they undergo a variety of cell-cell interactions, some of which are detrimental to their survival. This phase is particularly critical because in this hostile environment, the tumor cells are directly confronted with effectors of the host immune response. The vast majority of circulating tumor cells do not survive this stage (2, 3). NK<sup>3</sup> cells provide the most effective antitumor cell activity in the blood stream, at least in mice. Metastasis is more pronounced in mice that have NK cells with an impaired lytic activity due to a genetic defect (4). Also, depletion of NK cells results in strongly increased metastasis (5, 6). This has been demonstrated in many different tumor models and models of experimental as well as spontaneous metastasis (5-7). The exact mechanisms by which NK cells recognize and destroy tumor cells are not completely understood, but it is clear that both processes require direct contact with the target cell (8). It is not known how some tumor cells manage to avoid contact with NK cells to escape their cytolytic action.

Despite the impressive antimetastatic effect of NK cells, there is still a population of tumor cells that escapes the host immune response

and completes the metastatic cascade. Apparently, the tumor cells can make use of host mechanisms for protection during the hematogenous phase of metastasis. It is still unclear which tumor cell properties determine survival in the blood. Activation of platelets by tumor cells is considered to be an important step (1). It has been reported that the capability of mouse as well as human tumor cells to induce platelet aggregation *in vitro* correlates positively with their metastatic potential *in vivo* (9). This finding led to the assumption that platelets provide support for tumor cells to adhere to and extravasate through the endothelium and the subendothelial matrix. Interference with any step of tumor cell-platelet interaction always resulted in diminished metastasis in experimental settings. The integrins gpIIb/IIIa and gpIb on the platelet membrane have been found to be relevant interaction molecules for tumor cells to induce platelet aggregation (10). It has also been demonstrated that platelet depletion with an anti-platelet serum or inhibition of  $\beta_3$ -integrins with competing peptides drastically decreased the number of fibrosarcoma cell colonies in the lung (11-13). Despite many *in vivo* investigations demonstrating the importance of platelets for metastasis and different proposed mechanisms for platelet action based on *in vitro* studies, the critical platelet-dependent step in the metastatic cascade has not yet been identified.

The aim of the present study was to analyze the role of NK cells and platelets in the hematogenous phase of metastasis. Here we demonstrate for the first time that platelets directly protect tumor cells from NK cell lysis *in vitro* as well as *in vivo*. In the model of experimental metastasis using NK-sensitive and NK-resistant tumor cells, platelets were only required for successful metastasis when the tumor cells were NK susceptible. No contribution of platelets to tumor cell extravasation other than preventing tumor cell destruction by NK cells was evident. Platelets inhibited NK tumor cell lysis by aggregating around the tumor cells. Because protection is dependent on the number of platelets and their aggregation but independent of MHC class I molecules, surface shielding is proposed as the main protective mechanism.

## MATERIALS AND METHODS

**Animals.** Specific pathogen-free female C3H/HeN, DBA/2, and C57Bl/6 mice 5-7 weeks of age were obtained from Charles River (Sulzfeld, Germany). The  $\beta_2$ -microglobulin-deficient mice (14) were kindly provided by I. Autenrieth (LMU, Pettenkofer-Institut, Munich, Germany) and B. Kyewski (Deutsches Krebsforschungszentrum, Heidelberg, Germany).

**Tumor Cells.** CFS1/LacZ is a *lacZ* gene-transduced methylcholanthrene-induced fibrosarcoma cell line of C3H/HeN mouse origin (15). ESb-L.NA-10s, a *lacZ* gene-transduced ESb cell line derived from the highly metastatic subline of the methylcholanthrene-induced DBA/2 lymphoma L5178YE (Eb; 11), was kindly provided by V. Schirmacher (Deutsches Krebsforschungszentrum, Heidelberg, Germany). B16F10 melanoma cells derived from C57Bl/6 mice were kindly provided by A. Bosserhoff (Institut für Pathologie, Universität Regensburg, Regensburg, Germany). As target cells for the *in vitro* NK cytotoxicity assay, YAC1 Moloney virus-induced lymphoma cells were used. All cells were cultured in RPMI 1640 supplemented with 10% heat-inactivated FCS, 100 IU/ml penicillin, and 0.1 mg/ml streptomycin (all from Life Technologies, Inc., Eggenstein, Germany) in a humidified atmosphere containing 5% CO<sub>2</sub> at 37°C. YAC1 cell culture medium also contained 50  $\mu$ M  $\beta$ -mercaptoethanol (Merck, Darmstadt, Germany).

**Reagents.** The monoclonal rat-anti-mouse interleukin 2 receptor  $\beta$  chain IgG2b-secreting hybridoma (TM- $\beta$ 1) was a generous gift of T. Tanaka (Bio-

Received 9/28/98; accepted 1/21/99.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

<sup>1</sup> This work was supported by Grant Ma760/6-3 from the Deutsche Forschungsgemeinschaft.

<sup>2</sup> To whom requests for reprints should be addressed, at Institute of Pathology/Tumorimmunology, University of Regensburg, F.-J.-Strauss Allee, D-93042 Regensburg, Germany. Phone: 49 941 944 6622; Fax: 49 941 944 6602; E-mail: daniela.maennel@klinik.uni-regensburg.de.

<sup>3</sup> The abbreviations used are: NK, natural killer; MAb, monoclonal antibody; X-gal, 5-bromo-4-chloro-3-indolyl- $\beta$ -D-galactopyranoside.

medical Research Center, Osaka University Medical School, Japan). The antibodies were used as described (16). Polyclonal rat IgG (Sigma, Deisenhofen, Germany) was used as control antibody. Polyclonal rabbit anti-mouse platelet serum was generated as described (12), and 100  $\mu$ l were injected i.p. per mouse for induction of thrombocytopenia. The anti-mouse platelet MAb MWReg30 (rat IgG1) was generated by fusion of mouse myeloma cells (X63.Ag8.653) with spleen cells from a rat immunized with purified mouse platelets (11). The antigen recognized by MWReg30 is the fibrinogen receptor (gpIIb/IIIa, CD41) as shown by sequencing of the precipitated material. Affinity-purified MWReg30 was labeled with FITC (Sigma) at a FITC:protein ratio of 3:1 or with phycoerythrin (Sigma) at a phycoerythrin:protein ratio of 2:1 by standard methods and separated by gel filtration on a PD-10 column (Pharmacia). Hirudin (Serva, Heidelberg, Germany), apyrase grade III (Sigma), high molecular weight heparin (Sigma), and antibodies to P-selectin (PharMingen, Hamburg, Germany) were purchased.

**Experimental Metastasis.** CFS1/lacZ tumor cells after detachment with a trypsin (0.05%)-EDTA (0.02%) solution (Life Technologies, Inc.) and ESb-L.NA-10s tumor cells were washed twice. CFS1/lacZ ( $1 \times 10^6$ ) or ESb-L.NA-10s cells ( $2 \times 10^5$ ) in 0.2 ml medium were injected into the lateral tail vein of mice. Washed B16F10 cells ( $1 \times 10^5$ ) were injected in 0.2 ml culture medium retroorbitally. Because of the high number of lung colonies formed in NK cell-depleted mice, the number of CFS1/lacZ tumor cells was reduced as indicated in the figure legends to obtain evaluable numbers of metastases. Animals were killed by cervical dislocation 3 days after CFS1/lacZ or ESb-L.NA-10s tumor cell inoculation. To quantify micrometastases, cryosections of the lungs from mice injected with CFS1/lacZ cells or of the livers from mice injected with ESb-L.NA-10s cells were fixed in formaldehyde (2%)/glutaraldehyde (0.2%; Merck) in PBS for 10 min at 4°C. After washing with PBS, the sections were incubated in X-gal staining solution consisting of X-gal [1 mg/ml; AppliChem, Darmstadt, Germany; stock solution of 40 mg of X-gal dissolved in 1 ml of *N,N*-dimethylformamide (Merck)] diluted in 5 mM  $K_3Fe(CN)_6$ , 5 mM  $K_4Fe(CN)_6 \cdot 3H_2O$ , 2 mM  $MgCl_2$ , 0.01% (w/v) sodium deoxycholate, and 0.02% (v/v) NP40 (all from Sigma) in PBS for 3–12 h at 37°C. The organs were rinsed with PBS and stained with eosin. Tumor colonies were determined by counting the metastatic foci microscopically using a measuring grid. Tumor colonies in at least six different sections per organ were counted. The results are given as mean  $\pm$  SD colonies/mm<sup>2</sup>. To determine the number of surface metastases after B16F10 injection, the mice were killed on day 10, lungs and livers were removed and fixed in 4% PBS-buffered formaldehyde, and surface metastases were counted.

To calculate the total number of CFS1/lacZ micrometastases per lung, the lung volume was determined by water displacement. The area of 1 mm<sup>2</sup> of a section of 50  $\mu$ m thickness represents a volume of 0.05 mm<sup>3</sup>. On the basis of this assumption, a calculation of tumor foci for the whole organ was performed because CFS1/lacZ cells colonize uniformly in all regions of the lung.

**NK Cytotoxicity Assay.** Cytotoxic activity was tested in a standard 4-h <sup>51</sup>Cr-release assay. Briefly, splenic effector cells were cultured with YAC-1 target cells labeled with <sup>51</sup>Cr (NEN DuPont, Bad Homburg, Germany) at E:T ratios of 100:1, 50:1, and 25:1 for 90 min in quadruplicates for 4 h at 37°C. Label release into the supernatant was used to calculate the cytotoxicity in % =  $(a - b)/(c - b) \times 100$ , where *a* is cpm released in the test well, *b* is spontaneous release from target cells without addition of effector cells, and *c* is total release. For supernatant transfer experiments, 2-h supernatants from platelets or platelets cocultured with YAC1 cells at a ratio of 10,000 platelets per YAC1 cell were transferred to the NK cytotoxicity assay without any further dilution. Spontaneous release was always <10%.

**Platelet Preparation.** Mice were bled retroorbitally under ether anesthesia, and blood of 10 mice was pooled into a tube containing 0.5 ml 0.1 M sodium citrate. Platelet-rich plasma was obtained by centrifugation at 300  $\times$  g for 10 min at room temperature. The platelets were packed by centrifugation at 1300  $\times$  g for 10 min, washed three times with culture medium, and used immediately. Isolated platelets did not show signs of activation or degranulation as tested by fluorescence-activated cell sorter analysis. To determine platelet numbers in mice, blood (20  $\mu$ l) was obtained from the retroorbital plexus using siliconized microcapillaries and immediately diluted 1:100 in Unopette kits (Becton Dickinson, Heidelberg, Germany). The diluted blood sample was allowed to settle for 20 min in an improved Neubauer hemocytometer, and platelets were counted under phase contrast at  $\times 400$ .

**Flow Cytometry.** Tumor cells were harvested as described above, counted, resuspended in culture medium to a final concentration of  $10^5$  cells/ml, and cocultured with platelets in different ratios for 30 min at 37°C. The cells were subsequently stained with MAb MWReg30-FITC or control rat IgG-FITC at a final concentration of 5  $\mu$ g/ml for 20 min on ice and analyzed on a FACScan (Becton Dickinson; 11). Cells were gated by forward/side scatter characteristics.

**Statistics.** If not indicated otherwise in the figure legends, results are expressed as mean values  $\pm$  SD for five mice per group.

## RESULTS

**Effect of NK Cell Depletion on Metastasis.** The role of NK cells was analyzed in a model of experimental metastasis by injecting syngeneic tumor cells i.v. and quantitating tumor colonies in the target organ. NK cell-depletion was achieved by injection of MAb to the interleukin 2 receptor  $\beta$  chain (TM- $\beta$ 1; 16). This treatment has been shown to selectively and completely eliminate splenic NK functions of mice without affecting T-cell functions. Depletion of NK cells, as evidenced by the absence of any NK lytic activity in the spleen of antibody-treated mice (data not shown), resulted in strongly increased numbers of CFS1 lung colonies compared with control animals (Fig. 1). This effect was so strong that to distinguish between individual metastatic foci in the NK-depleted mice, the number of inoculated CFS1 tumor cells was reduced from  $1 \times 10^6$  to  $1 \times 10^5$  per animal. Similar results were obtained when lung colonization by B16 melanoma cells was compared in normal *versus* NK-depleted mice (Fig. 1). Not only increased numbers of B16 colonies were detected in the lungs of NK cell-depleted mice, but the livers were also filled with metastases. This is in clear contrast to the metastatic behavior of B16 cells in normal mice, where no liver metastasis is observed. Colony formation of the NK-resistant ESb thymoma cells in the liver was not affected by NK cell depletion (Fig. 1).

**Interaction of Platelets with Tumor Cells *in Vitro*.** The role of platelets in metastasis was investigated to find out how some tumor cells avoid being killed by NK cells. CFS1, B16, and ESb tumor cells were tested *in vitro* for their potential to interact with platelets. Tumor cells were cocultured with freshly isolated platelets, and adhesion of platelets to the tumor cell membrane was determined by flow cytometry. Bound platelets were stained with MWReg30, a fluoresceinated mouse platelet/megacaryocyte-specific rat MAb directed against the fibrinogen receptor (gpIIb/IIIa, CD41; 11). Single cells were gated by




Fig. 1. Metastasis in NK-depleted mice. Mice received TM- $\beta$ 1 i.p. to deplete NK cells 1 week before the i.v. injection of CFS1 ( $1 \times 10^5$ ), B16 ( $1 \times 10^5$ ), or ESb ( $2 \times 10^5$ ) tumor cells. The number of micrometastases per mm<sup>2</sup> was quantified on stained lung sections for CFS1 or on liver sections for ESb tumor cells 4 days after tumor cell injection. Surface metastases were counted on lungs on day 10 after B16 tumor cell injection. The results are given as means; bars, SD.




Fig. 2. Platelet-specific staining of tumor cells after coculture with platelets. Tumor cells were stained with the fluoresceinated monoclonal rat anti-mouse CD41 (fibrinogen receptor, gpIIb/IIIa) antibody (MWReg30,  $5 \mu\text{g}/10^5$  tumor cells/ml). A, in the cytofluorometric analysis, the shaded area represents nonspecific background staining of the CFS1, B16, or ESb tumor cells with MWReg30. Positive staining with MWReg30 was found when platelets (1000 platelets/tumor cell) were added to CFS1 and B16 tumor cells. B, microscopic analysis of a coculture of platelets with CFS1 tumor cells (1000 platelets/tumor cell; left, phase contrast; right, fluorescence microscopy;  $\times 400$ ).

forward/side scatter characteristics, which were not altered significantly by bound platelets. CFS1 and B16 cells in contrast to ESb cells strongly induced platelet aggregation, leading to deposition of platelet aggregates on their surface (Fig. 2A). The intensity of the platelet-specific marker signal associated with the tumor cells was dependent on the number of added platelets (data not shown). Microscopic inspection revealed individual tumor cells covered with platelets (Fig. 2B) and, in addition, large aggregates of tumor cells and platelets that had been excluded in the flow cytometric analysis. These data showed that CFS1 and B16 cells strongly activated platelets and induced their aggregation, whereas ESb cells did not.

**Effect of Platelet Depletion on Metastasis.** To investigate the significance of such platelet aggregation on metastasis *in vivo*, mice were rendered thrombocytopenic 24 h before tumor cell inoculation by injection of rabbit anti-mouse platelet serum. This treatment decreased the number of circulating platelets to  $<10\%$  of the normal value (from  $1.0\text{--}1.2 \times 10^6/\mu\text{l}$  to  $1.0 \times 10^5/\mu\text{l}$ ) and kept it at this level for at least 48 h (data not shown). Such platelet depletion resulted in

a reduction of metastasis of CFS1 and B16 cells by  $>95\%$  compared to metastasis in animals with normal platelet numbers (Fig. 3). Liver colonization with ESb cells, however, was not affected by platelet depletion.

**Effect of NK Cell Depletion and Platelet Depletion on Metastasis.** To investigate whether NK cells and platelets play counteracting roles in metastasis, mice were depleted of NK cells by TM- $\beta 1$  treatment, and the role of platelets in this NK cell-free system was evaluated. Metastasis of CFS1 and B16 cells in NK cell-depleted mice was high, and no difference in the number of metastatic foci between platelet-depleted and control group was measurable (Fig. 4). Metastasis of NK-resistant ESb cells was not affected by either treatment (Fig. 4).

The efficacy of this platelet-mediated protection was estimated with CFS1 tumor cells by calculating the percentage of inoculated tumor cells that reached the lung and formed micrometastases. On the basis of a mean lung volume of  $350 \mu\text{l} \pm 50 \mu\text{l}$ , it was found that: (a) in NK cell-depleted mice, virtually all inoculated tumor cells (93%) had formed metastatic foci; and (b) thrombocytopenia did not alter this






Fig. 3. Metastasis in thrombocytopenic mice. Mice had received either rabbit anti-mouse platelet serum or control rabbit serum (100  $\mu$ l) i.p. 24 h before the i.v. injection of CFS1 ( $1 \times 10^5$ ), B16 ( $1 \times 10^5$ ), or ESb ( $2 \times 10^5$ ) tumor cells. The number of micrometastases per  $\text{mm}^2$  was quantified on stained lung sections for CFS1 or on liver sections for ESb tumor cells 4 days after tumor cell injection. Surface metastases were counted on lungs on day 10 after B16 tumor cell injection. The results are given as means; bars, SD.




Fig. 4. Metastasis in thrombocytopenic mice after NK cell depletion. Mice had received either TM- $\beta$ 1 or control rat immunoglobulin (1 mg in 100  $\mu$ l PBS) i.p. 1 week before and either rabbit anti-mouse platelet serum or control rabbit serum (100  $\mu$ l) i.p. 24 h before the i.v. injection of CFS1 ( $1 \times 10^6$  in normal and  $5 \times 10^5$  in TM- $\beta$ 1-treated mice), B16 ( $1 \times 10^5$ ), or ESb ( $2 \times 10^5$ ) tumor cells. The number of micrometastases per  $\text{mm}^2$  was quantified on stained lung sections for CFS1 or on liver sections for ESb tumor cells 4 days after tumor cell injection. Surface metastases were counted on lungs on day 10 after B16 tumor cell injection. The results are given as means; bars, SD.

rate of colonization. In normal NK cell-bearing mice, 5.5% of inoculated tumor cells colonized the lungs. Platelet depletion reduced the rate of tumor cell colonization to 0.2%, demonstrating the potential of platelets to prevent NK cell lysis of CFS1 tumor cells (Table 1).

**Effect of Platelets on NK Cell Cytotoxicity *in Vitro*.** Addition of increasing numbers of platelets into the standard NK assay system resulted in a platelet number-dependent inhibition of YAC1 killing (Fig. 5). To test a possible involvement of platelet MHC class I molecules for inhibition of NK cytotoxicity, we used platelets from

different allogeneic mouse strains and, in addition, platelets from  $\beta_2$ -microglobulin-deficient mice, which express little if any functional MHC class I molecules (14). All platelets inhibited lysis of YAC1 NK target cells to a comparable extent (Table 2), indicating a MHC class I-independent protection mechanism. Blockage of platelet aggregation with hirudin, a specific thrombin antagonist, completely prevented the inhibitory effect, demonstrating thrombin dependency of aggregation. Addition of heparin, or the ADP scavenger apyrase, as well as addition of blocking antibodies to P-selectin reversed the platelet-mediated protection by about 50%. Correspondingly, these agents also inhibited platelet aggregation around tumor cells as determined by flow cytometric analysis and microscopic inspection. Whereas in the absence of antiaggregating agents large aggregates and 33% of the gated tumor cells were found to bind platelets, hirudin and anti-P-selectin antibodies prevented the formation of large aggregates and reduced the number of platelet-binding tumor cells to 3 and 9%, respectively. In the presence of heparin and apyrase, the tumor cell-platelet aggregation was clearly reduced, and only 16% of the gated tumor cells stained positive for platelets after heparin and 12% after apyrase addition. Transfer of supernatants from platelets or from platelets cocultured with YAC1 cells at a ratio of 10,000 platelets per YAC1 cell also inhibited lysis of NK target cells to about 30% as shown in Table 2.

**DISCUSSION**

Our studies show that depletion of NK cells increased the number of CFS1 and B16 tumor colonies in a model of experimental metastasis, demonstrating the NK sensitivity of these tumor cells *in vivo*. In the case of CFS1 fibrosarcoma cells, virtually all inoculated tumor cells colonized the lungs after NK cell depletion, whereas in NK-bearing mice, <10% developed into metastases. Comparable results were obtained with B16 melanoma cells, which besides metastasizing more strongly to the lungs also metastasized into the liver after NK cell depletion, indicating that the observed metastasis-enhancing effect after NK depletion was not restricted to the lung. These data confirm the notion that NK cells provide an effective antitumoral defense in the blood of mice. Addressing the question how some tumor cells manage to escape NK cell cytolytic activity in the blood, we found that metastasis of two NK-sensitive tumor cell lines, CFS1 and B16, was platelet-dependent, whereas the NK-resistant ESb tumor cells metastasized platelet independently.

Many different mechanisms have been proposed by which platelets may promote metastasis. These include: (a) stabilizing tumor cell arrest in the vasculature; (b) stimulation of tumor cell proliferation; (c) promoting tumor cell extravasation by potentiating tumor cell-induced endothelial cell retraction; and (d) enhancing tumor cell interaction with the extracellular matrix as reviewed by Honn *et al.* (1). In the absence of NK cells with all three tumor cell lines, equally strong metastasis was observed in both thrombocytopenic and control mice. Under these conditions, virtually all inoculated fibrosarcoma cells metastasized, irrespective of the presence or absence of platelets, suggesting that, at least in our model of experimental metastasis,

Table 1 Effect of NK cell depletion and platelet depletion on lung metastasis

Numbers of micrometastases and percentage of inoculated tumor cells were assessed based on counted tumor lung colonies, thickness of tissue sections, and lung volume.

NK cells	Platelets	Inoculated tumor cells	Micrometastases per			% of inoculated tumor cells
			$\text{mm}^2$	$\text{mm}^3$	Lung	
Present	Present	$1 \times 10^6$	8	160	$5.5 \times 10^4$	5.5
Present	Absent	$1 \times 10^6$	0.4	8	$2.8 \times 10^3$	0.3
Absent	Present	$3 \times 10^4$	4	80	$2.8 \times 10^4$	93
Absent	Absent	$3 \times 10^4$	4	80	$2.8 \times 10^4$	93

stabilization of the tumor cells in the vasculature and enhancement of tumor cell interactions with the subendothelial matrix are not essential but may represent platelet effects of secondary importance.

On the other hand, in the presence of NK cells, lack of protecting platelets is detrimental to NK-sensitive tumor cells, as shown in different metastasis models where platelet depletion or inhibition of platelet aggregation clearly reduced metastasis (11, 12, 15, 17). Also, an inverse correlation of the anticoagulant thrombomodulin expression and intrahepatic metastasis in human hepatocellular carcinoma has been reported (18). Conversely, measures leading to enhanced platelet aggregation, e.g., provided by inflammatory stimuli, correlated with enhanced metastasis (1, 13). In both human and rat studies, organs that are preferred sites for metastasis have been shown to have significantly higher procoagulant activity than nonpreferred organs (19). Our flow cytometric data show that not all tumor cells bind platelets to the same extent. The NK-resistant ESb tumor cells did not induce significant platelet aggregation on their surface. Also, in the case of the CFS1 and B16 tumor cells, a subpopulation of the cells bound platelets much more efficiently than the rest, as indicated by higher fluorescence intensity after staining with the FITC-labeled, platelet-specific antibody MWReg30. This subpopulation with higher platelet-aggregation activity may represent those tumor cells that are most efficiently protected against NK cell lysis.

Different adhesion molecules have been suggested to be involved in this tumor cell-platelet aggregation phenomenon. The finding that blocking antibodies to P-selectin inhibited platelet aggregation around tumor cells and partially reversed the platelet-mediated inhibition of NK lysis *in vitro* supports the hypothesis that this molecule plays a role in platelet-tumor cell adhesion (20–24). Thrombospondin (25) as well as the fibrinogen receptor (gpIIb/IIIa, CD41; 26) and tumor cell  $\alpha v$  integrins (27) may be involved in tumor cell attachment to platelet thrombi. Ultrastructural studies with the human carcinosarcoma Colo 526 revealed a two-step process in which a first event of adhesion and degranulation of individual platelets in contact with a glycoprotein or glycolipid on the tumor cell membrane was followed by a wave of aggregation involving residual platelets (28).

Besides providing a mere physical barrier and steric hindrance between tumor cells and NK cells, platelets may also interfere with recognition or killing of tumor cells by NK cells. In covering the tumor cells, platelets bring MHC class I antigen into the vicinity of the tumor cell surface, which could down-regulate NK cytotoxic activity (29). However, because platelet-caused NK inhibition was independent of the platelet donor haplotype and was equally observed with platelets from  $\beta_2$ -microglobulin-deficient mice, a MHC class I-dependent inhibitory mechanism is unlikely. An alternative interpretation is that platelets do not (only) shield tumor cells but inhibit cytolytic




Fig. 5. Inhibition of splenic NK activity by the addition of platelets. Lytic activity of spleen cell suspensions in the absence (●) or presence of 1,000 (■) or 10,000 (▲) platelets per YAC1 target cell was determined in a 4-h  $^{51}\text{Cr}$ -release NK assay (spontaneous release, 4.9%). Bars, SD.

Table 2 Inhibition of NK activity by the addition of platelets

The inhibitory capacity of platelets from mice of different strains and the influence of aggregation inhibitors hirudin (1 unit/ml), heparin (1 unit/ml), apyrase (5 units/ml), anti-P-selectin MAb (10  $\mu\text{g/ml}$ ), 2-h platelet supernatant, or 2-h platelet + YAC1 supernatant were determined in a 4-h  $^{51}\text{Cr}$ -release NK assay using C3H/HeN spleen cells as source of NK cells. The data given were obtained with an E:T ratio of 100:1 and in the presence of 10,000 platelets per YAC1 tumor cell. Specific lysis without the addition of platelets or inhibitors was  $36.6 \pm 1.2\%$  in A,  $46.5 \pm 1.1\%$  in B, and  $11.6 \pm 0.4\%$  in C.

Platelet donor mouse strain	Added substance	Inhibition of specific lysis %
A		
—	—	0
C3H/HeN	—	$54.7 \pm 4.5$
C57Bl/6	—	$56.1 \pm 1.1$
C57Bl/6/SVJ129	—	$53.8 \pm 2.5$
NMRI	—	$64.2 \pm 0.8$
$\beta_2$ -Microglobulin <sup>-/-</sup>	—	$46.6 \pm 2.4$
B		
C3H/HeN	Hirudin	$0.5 \pm 4.4$
C3H/HeN	Heparin	$41.3 \pm 3.2$
C3H/HeN	Apyrase	$38.1 \pm 4.3$
C3H/HeN	Anti-P-selectin	$36.0 \pm 4.5$
C3H/HeN	Rat IgG	$65.8 \pm 7.0$
C		
—	—	0
C3H/HeN	—	$77.4 \pm 4.6$
—	Platelet supernatant	$32.8 \pm 5.2$
—	Platelet + YAC1 Supernatant	$30.4 \pm 4.8$

functions of NK cells by either release of suppressive or tumor cell protective factors (30, 31). The two theories are not mutually exclusive. Our supernatant transfer experiments indicate that platelet-derived soluble inhibitory factors might, indeed, be involved.

The role of the NK system for tumor defense in humans is still a matter of debate. This study shows that the main contribution of platelets to metastasis seems to consist in protection of tumor cells from NK lysis. Clinical studies have shown that anticoagulant therapy improves tumor response rates and survival of small cell lung cancer patients (32). It remains to be carefully analyzed in further clinical studies whether therapies with anticoagulants could be particularly useful in reducing the metastatic spread in cancer patients.

## REFERENCES

- Honn, K. V., Tang, D. G., and Crissman, J. D. Platelets and cancer metastasis: a causal relationship? *Cancer Metastasis Rev.*, 11: 325–351, 1992.
- Roos, E. Cellular adhesion, invasion and metastasis. *Biochim. Biophys. Acta*, 738: 263–284, 1984.
- Liotta, L. A. Cancer cell invasion and metastasis. *Sci. Am.*, 266: 54–59, 62–63, 1992.
- Talmadge, J. E., Meyers, K. M., Prieur, D. J., and Starkey, J. R. Role of NK cells in tumour growth and metastasis in beige mice. *Nature (Lond.)*, 284: 622–624, 1980.
- Hanna, N. The role of natural killer cells in the control of tumor growth and metastasis. *Biochim. Biophys. Acta*, 780: 213–226, 1985.
- Wiltout, R. H., Herberman, R. B., Zhang, S. R., Chirigos, M. A., Ortaldo, J. R., Green, K. M. J., and Talmadge, J. E. Role of organ-associated NK cells in decreased formation of experimental metastases in lung and liver. *J. Immunol.*, 134: 4267–4275, 1985.
- Gorelik, E., Bere, W., and Herberman, R. B. Role of NK cells in the antimetastatic effect of anticoagulant drugs. *Int. J. Cancer*, 33: 87–94, 1984.
- Storkus, W. J., and Dawson, J. R. Target structures involved in natural killing (NK): characteristics, distribution, and candidate molecules. *Crit. Rev. Immunol.*, 10: 393–416, 1991.
- Heinmöller, E., Weinel, R. J., Heidtmann, H. H., Salge, U., Seitz, R., Schmitz, I., Müller, K. M., and Zirngibl, H. Studies on tumor cell-induced platelet aggregation in human lung cancer cell lines. *J. Cancer Res. Clin. Oncol.*, 122: 735–744, 1996.
- Kitagawa, H., Yamamoto, N., Yamamoto, K., Tanoue, K., Kosaki, G., and Yamazaki, H. Involvement of platelet membrane glycoprotein Ib and glycoprotein IIb/IIIa complex in thrombin-dependent and -independent platelet aggregations induced by tumor cells. *Cancer Res.*, 49: 537–541, 1989.
- Stoelcker, B., Hafner, M., Orosz, P., Nieswandt, B., and Männel, D. N. Role of adhesion molecules and platelets in TNF-induced adhesion of tumor cells to endothelial cells: implications for experimental metastasis. *J. Inflammation*, 46: 155–167, 1996.
- Mahalingam, M., Ugen, K. E., Kao, K. J., and Klein, P. A. Functional role of platelets in experimental metastasis studied with cloned murine fibrosarcoma cell variants. *Cancer Res.*, 48: 1460–1464, 1988.
- Männel, D. N., Orosz, P., Hafner, M., and Falk, W. Mechanisms involved in metastasis enhanced by inflammatory mediators. *Circ. Shock*, 44: 9–13, 1994.

14. Zijlstra, M., Bix, M., Simister, N. E., Loring, J. M., Raulet, D. H., and Jaenisch, R.  $\beta$ 2-Microglobulin deficient mice lack CD4<sup>+</sup> cytolytic T cells. *Nature (Lond.)*, *344*: 742–746, 1990.
15. Hafner, M., Orosz, P., Krüger, A., and Männel, D. N. TNF promotes metastasis by impairing natural killer cell activity. *Int. J. Cancer*, *66*: 388–392, 1996.
16. Tanaka, T., Kitamura, F., Nagasaka, Y., Kuida, K., Suwa, H., and Miyasaka, M. Selective long-term elimination of natural killer cells *in vivo* by an anti-interleukin 2 receptor  $\beta$  chain monoclonal antibody in mice. *J. Exp. Med.*, *178*: 1103–1107, 1993.
17. Tzanakakis, G. N., Agarwal, K. C., and Vezeridis, M. P. Prevention of human pancreatic cancer cell-induced hepatic metastasis in nude mice by dipyridamole and its analog RA-233. *Cancer (Phila.)*, *71*: 2466–2471, 1993.
18. Suehiro, T., Shimada, M., Matsumata, T., Taketomi, A., Yamamoto, K., and Sugimachi, K. Thrombomodulin inhibits intrahepatic spread in human hepatocellular carcinoma. *Hepatology*, *21*: 1285–1290, 1995.
19. Carty, N. J., Taylor, I., Roath, O. S., el Baruni, K., and Francis, J. L. Tissue procogulant activity may be important in sustaining metastatic tumour growth. *Clin. Exp. Metastasis*, *10*: 175–181, 1992.
20. Boukerche, H., Ruchaud Sparagano, M. H., Rouen, C., Brochier, J., Kaplan, C., and McGregor, J. L. A monoclonal antibody directed against a granule membrane glycoprotein (GMP-140/PADGEM, P-selectin, CD62P) inhibits ristocetin-induced platelet aggregation. *Br. J. Haematol.*, *92*: 442–451, 1996.
21. Goetz, D. J., Ding, H., Atkinson, W. J., Vachino, G., Camphausen, R. T., Cumming, D. A., and Luscinskas, F. W. A human colon carcinoma cell line exhibits adhesive interactions with P-selectin under fluid flow via a PSGL-1-independent mechanism. *Am. J. Pathol.*, *149*: 1661–1673, 1996.
22. Toyoshima, M., Nakajima, M., Yamori, T., and Tsuruo, T. Purification and characterization of the platelet-aggregating sialoglycoprotein gp44 expressed by highly metastatic variant cells of mouse colon adenocarcinoma 26. *Cancer Res.*, *55*: 767–773, 1995.
23. Stone, J. P., and Wagner, D. D. P-selectin mediates adhesion of platelets to neuroblastoma and small cell lung cancer. *J. Clin. Invest.*, *92*: 804–813, 1993.
24. Inufusa, H., Kojima, N., Yasutomi, M., and Hakomori, S. Human lung adenocarcinoma cell lines with different lung colonization potential (LCP), and a correlation between expression of sialosyl dimeric Le(x) (defined by MAb FH6) and LCP. *Clin. Exp. Metastasis*, *9*: 245–257, 1991.
25. Boukerche, H., Berthier Vergnes, O., Tabone, E., Bailly, M., Dore, J. F., and McGregor, J. L. Thrombospondin modulates melanoma-platelet interactions and melanoma tumour cell growth *in vivo*. *Br. J. Cancer*, *72*: 108–116, 1995.
26. Felding Habermann, B., Habermann, R., Saldivar, E., and Ruggeri, Z. M. Role of  $\beta$ 3 integrins in melanoma cell adhesion to activated platelets under flow. *J. Biol. Chem.*, *271*: 5892–5900, 1996.
27. Dardik, R., Kaufmann, Y., Savion, N., Rosenberg, N., Shenkman, B., and Varon, D. Platelets mediate tumor cell adhesion to the subendothelium under flow conditions: involvement of platelet GPIIb-IIIa and tumor cell  $\alpha$ (v) integrins. *Int. J. Cancer*, *70*: 201–207, 1997.
28. Bradley, C. J., Dauer, R. J., Thurlow, P. J., and Connellan, J. M. Characterization of platelet aggregation induced by the human carcinosarcoma Colo 526: role of platelet activation, tumor cell cytoskeleton and tumor cell plasma membrane. *Pathology*, *29*: 189–195, 1997.
29. Moretta, A., Vitale, M., Bottino, C., Orengo, A. M., Morelli, L., Augugliaro, R., Barbaresi, M., Ciccone, E., and Moretta, L. P58 molecules as putative receptors for major histocompatibility complex (MHC) class I molecules in human natural killer (NK) cells. Anti-p58 antibodies reconstitute lysis of MHC class I-protected cells in NK clones displaying different specificities. *J. Exp. Med.*, *178*: 597–604, 1993.
30. Shau, H., Roth, M. D., and Golub, S. H. Regulation of natural killer function by nonlymphoid cells. *Nat. Immun.*, *12*: 235–249, 1993.
31. Philippe, C., Philippe, B., Fouqueray, B., Perez, J., Leuret, M., and Baud, L. Protection from tumor necrosis factor-mediated cytotoxicity by platelets. *Am. J. Pathol.*, *143*: 1713–1723, 1993.
32. Zacharski, L. R., Henderson, W. G., Rickles, F. R., Forman, W. B., Cornell, C. J., Jr., Forcier, R. J., Edwards, R. L., Headley, E., Kim, S. H., O'Donnell, J. F., *et al.* Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75. *Cancer (Phila.)*, *53*: 2046–2052, 1984.

# Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

## Lysis of Tumor Cells by Natural Killer Cells in Mice Is Impeded by Platelets

Bernhard Nieswandt, Michael Hafner, Bernd Echtenacher, et al.

*Cancer Res* 1999;59:1295-1300.

**Updated version** Access the most recent version of this article at:  
<http://cancerres.aacrjournals.org/content/59/6/1295>

**Cited articles** This article cites 31 articles, 7 of which you can access for free at:  
<http://cancerres.aacrjournals.org/content/59/6/1295.full#ref-list-1>

**Citing articles** This article has been cited by 63 HighWire-hosted articles. Access the articles at:  
<http://cancerres.aacrjournals.org/content/59/6/1295.full#related-urls>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link  
<http://cancerres.aacrjournals.org/content/59/6/1295>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.